Quipt Home Medical (NASDAQ:QIPT – Get Free Report) and BioRestorative Therapies (NASDAQ:BRTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Insider & Institutional Ownership
42.9% of Quipt Home Medical shares are held by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are held by institutional investors. 13.4% of Quipt Home Medical shares are held by company insiders. Comparatively, 25.5% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Quipt Home Medical and BioRestorative Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quipt Home Medical | 1 | 0 | 3 | 2 | 3.00 |
| BioRestorative Therapies | 0 | 0 | 1 | 0 | 3.00 |
Earnings & Valuation
This table compares Quipt Home Medical and BioRestorative Therapies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quipt Home Medical | $245.91 million | 0.46 | -$6.76 million | ($0.17) | -15.29 |
| BioRestorative Therapies | $377,000.00 | 35.98 | -$14.41 million | ($1.53) | -1.28 |
Quipt Home Medical has higher revenue and earnings than BioRestorative Therapies. Quipt Home Medical is trading at a lower price-to-earnings ratio than BioRestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Quipt Home Medical and BioRestorative Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quipt Home Medical | -2.90% | -6.70% | -2.94% |
| BioRestorative Therapies | -2,697.08% | -98.49% | -75.23% |
Risk & Volatility
Quipt Home Medical has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 62.62, indicating that its stock price is 6,162% more volatile than the S&P 500.
Summary
Quipt Home Medical beats BioRestorative Therapies on 8 of the 14 factors compared between the two stocks.
About Quipt Home Medical
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
About BioRestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for Quipt Home Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quipt Home Medical and related companies with MarketBeat.com's FREE daily email newsletter.
